IOVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Iovance Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Iovance Biotherapeutics, Inc. for alleged violations of federal securities laws, following a significant decline in the company's financial performance and misleading statements made to investors [1][2][3]. Financial Performance - Iovance reported a total product revenue of $49.3 million for Q1 2025, down from $73.7 million in the previous quarter [4]. - The company's full fiscal year 2025 revenue guidance was reduced from $450 million - $475 million to $250 million - $300 million, representing a reduction of over 40% at the midpoint [4]. Allegations - The lawsuit claims that Iovance's executives provided overly positive statements while concealing material adverse facts about the company's growth potential and its ability to meet demand for its treatments [3]. Legal Proceedings - Investors who purchased Iovance securities between May 9, 2024, and May 8, 2025, are encouraged to join the class action lawsuit, with a deadline to request lead plaintiff status by July 14, 2025 [2][5]. Representation - Bronstein, Gewirtz & Grossman, LLC represents investors on a contingency fee basis, meaning they will only collect fees if the case is successful [6][7].